The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Hydroxycarboxylic acid receptor 2 mediates dimethyl fumarate’s protective effect in EAE
Open accessAbstract
Taken orally, the drug dimethyl fumarate (DMF) has been shown to improve functional outcomes for patients with MS; however, it is unclear how DMF mediates a protective effect. DMF and, more so, its active metabolite, monomethyl fumarate, are known agonists of the hydroxycarboxylic acid receptor 2 (HCA₂), a G protein-coupled membrane receptor. Here, we evaluated the contribution of HCA₂ in mediating the protective effect afforded by DMF in EAE, a mouse model of MS. DMF treatment reduced neurological deficit, immune cell infiltration, and demyelination of the spinal cords in wild-type mice, but not in Hca2⁻/⁻ mice, indicating that HCA₂ is required for the therapeutic effect of DMF. In particular, DMF decreased the number of infiltrating neutrophils in a HCA₂-dependent manner, likely by interfering with neutrophil adhesion to endothelial cells and chemotaxis. Together, our data indicate that HCA₂ mediates the therapeutic effects of DMF in EAE. Furthermore, identification of HCA₂ as a molecular target may help to optimize MS therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neutrophil recruitment and function in health and inflammation
Kolaczkowska, E., & Kubes, P. (2013) · Nature Reviews Immunology · doi:10.1038/nri3399 · Cited by 5,472
Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
Gold, R., Kappos, L., Arnold, D. L., Bar-Or, A., Giovannoni, G., Selmaj, K., Tornatore, C., Sweetser, M. T., Yang, M., Sheikh, S. I., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114287 · Cited by 1,733
Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis
Fox, R. J., Miller, D. H., Phillips, J. T., Hutchinson, M., Havrdova, E., Kita, M., Yang, M., Raghupathi, K., Novas, M., Sweetser, M. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1206328 · Cited by 1,355
Linker, R. A., Lee, D.-H., Ryan, S., van Dam, A. M., Conrad, R., Bista, P., Zeng, W., Hronowsky, X., Buko, A., Chollate, S., et al. (2011) · Brain · doi:10.1093/brain/awq386 · Cited by 1,155 · cited 4×
“DMF and MMF covalently modify glutathione and KEAP-1, the inhibitor of the antioxidant transcription factor nuclear factor erythroid-derived 2–related factor 2 (NRF2), and induce hemoxy-genase-1 ( HMOX1 ), NADP(H) quinoline oxidoreductase-1 ( NQO1 ), and other genes (6, 7).”
InfluentialInnate immunity in the central nervous system
Ransohoff, R. M., & Brown, M. A. (2012) · Journal of Clinical Investigation · doi:10.1172/jci58644 · Cited by 1,034 · cited 1×
“By interfering with neutrophil recruitment, DMF may exert secondary effects on other immune cells in EAE and MS (24).”
PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect
Tunaru, S., Kero, J., Schaub, A., Wufka, C., Blaukat, A., Pfeffer, K., & Offermanns, S. (2003) · Nature Medicine · doi:10.1038/nm824 · Cited by 791
Self-citationFumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells
Ghoreschi, K., Brück, J., Kellerer, C., Deng, C., Peng, H., Rothfuss, O., Hussain, R. Z., Gocke, A. R., Respa, A., Glocova, I., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20100977 · Cited by 352
Carlson, T., Kroenke, M., Rao, P., Lane, T. E., & Segal, B. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20072404 · Cited by 272
Schilling, S., Goelz, S., Linker, R., Luehder, F., & Gold, R. (2006) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2006.03094.x · Cited by 271
β-Arrestin1 mediates nicotinic acid–induced flushing, but not its antilipolytic effect, in mice
Walters, R. W., Shukla, A. K., Kovacs, J. J., Violin, J. D., DeWire, S. M., Lam, C. M., Chen, J. R., Muehlbauer, M. J., Whalen, E. J., & Lefkowitz, R. J. (2009) · Journal of Clinical Investigation · doi:10.1172/jci36806 · Cited by 240
Cited by
Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases
Cuadrado, A., Rojo, A. I., Wells, G., Hayes, J. D., Cousin, S. P., Rumsey, W. L., Attucks, O. C., Franklin, S., Levonen, A.-L., Kensler, T. W., et al. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0008-x · Cited by 1,438
Microbiota metabolite short chain fatty acids, GPCR, and inflammatory bowel diseases
Sun, M., Wu, W., Liu, Z., & Cong, Y. (2017) · Journal of Gastroenterology · doi:10.1007/s00535-016-1242-9 · Cited by 1,047
The neuropharmacology of butyrate: the bread and butter of the microbiota-gut-brain axis
Stilling, R. M., van de Wouw, M., Clarke, G., Stanton, C., Dinan, T. G., & Cryan, J. F. (2016) · Neurochemistry International · doi:10.1016/j.neuint.2016.06.011 · Cited by 891
Transcription Factor NRF2 as a Therapeutic Target for Chronic Diseases: A Systems Medicine Approach
Cuadrado, A., Manda, G., Hassan, A., Alcaraz, M. J., Barbas, C., Daiber, A., Ghezzi, P., León, R., López, M. G., Oliva, B., et al. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014753 · Cited by 632
“, 2015) and leading to decreased neutrophil infiltration (Chen et al., 2014).”
BackgroundGPCR-Mediated Signaling of Metabolites
Husted, A. S., Trauelsen, M., Rudenko, O., Hjorth, S. A., & Schwartz, T. W. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.03.008 · Cited by 590
Targeting immunometabolism as an anti-inflammatory strategy
Pålsson-McDermott, E. M., & O’Neill, L. A. J. (2020) · Cell Research · doi:10.1038/s41422-020-0291-z · Cited by 577
Benefits of short-chain fatty acids and their receptors in inflammation and carcinogenesis
Sivaprakasam, S., Prasad, P. D., & Singh, N. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.04.007 · Cited by 571
The β-hydroxybutyrate receptor HCA2 activates a neuroprotective subset of macrophages
Rahman, M., Muhammad, S., Khan, M. A., Chen, H., Ridder, D. A., Müller-Fielitz, H., Pokorná, B., Vollbrandt, T., Stölting, I., Nadrowitz, R., et al. (2014) · Nature Communications · doi:10.1038/ncomms4944 · Cited by 427
Self-citationYan, Z., Gibson, S. A., Buckley, J. A., Qin, H., & Benveniste, E. N. (2018) · Clinical Immunology · doi:10.1016/j.clim.2016.09.014 · Cited by 318
Oxidative stress in multiple sclerosis: Central and peripheral mode of action
Ohl, K., Tenbrock, K., & Kipp, M. (2016) · Experimental Neurology · doi:10.1016/j.expneurol.2015.11.010 · Cited by 317
Dimethyl fumarate in the treatment of relapsing–remitting multiple sclerosis: an overview
Bomprezzi, R. (2015) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285614564152 · Cited by 301
Dimethyl fumarate treatment induces adaptive and innate immune modulation independent of Nrf2
Schulze-Topphoff, U., Varrin-Doyer, M., Pekarek, K., Spencer, C. M., Shetty, A., Sagan, S. A., Cree, B. A. C., Sobel, R. A., Wipke, B. T., Steinman, L., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1603907113 · Cited by 293
Fu, S.-P., Wang, J.-F., Xue, W.-J., Liu, H.-M., Liu, B.-R., Zeng, Y.-L., Li, S.-N., Huang, B.-X., Lv, Q.-K., Wang, W., et al. (2015) · Journal of Neuroinflammation · doi:10.1186/s12974-014-0230-3 · Cited by 270
Multiple sclerosis animal models: a clinical and histopathological perspective
Kipp, M., Nyamoya, S., Hochstrasser, T., & Amor, S. (2017) · Brain Pathology · doi:10.1111/bpa.12454 · Cited by 226
Chemical proteomic map of dimethyl fumarate–sensitive cysteines in primary human T cells
Blewett, M. M., Xie, J., Zaro, B. W., Backus, K. M., Altman, A., Teijaro, J. R., & Cravatt, B. F. (2016) · Science Signaling · doi:10.1126/scisignal.aaf7694 · Cited by 194
Brennan, M. S., Matos, M. F., Li, B., Hronowski, X., Gao, B., Juhasz, P., Rhodes, K. J., & Scannevin, R. H. (2015) · PLOS ONE · doi:10.1371/journal.pone.0120254 · Cited by 188
Food Fight: Role of Itaconate and Other Metabolites in Antimicrobial Defense
Luan, H. H., & Medzhitov, R. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.08.013 · Cited by 130
“…macrophage and monocyte response to LPS (Digby et al., 2012; Zandi-Nejad et al., 2013), inhibits progression of atherosclerosis (Lukasova et al., 2011), and inhibits lymphocyte infiltration in models of stroke and experimental autoimmune encephalomyelitis (Chen et al., 2014; Rahman et al., 2014).”
BackgroundA review of the mechanisms of action of dimethylfumarate in the treatment of psoriasis
Brück, J., Dringen, R., Amasuno, A., Pau‐Charles, I., & Ghoreschi, K. (2018) · Experimental Dermatology · doi:10.1111/exd.13548 · Cited by 128
Draheim, T., Liessem, A., Scheld, M., Wilms, F., Weißflog, M., Denecke, B., Kensler, T. W., Zendedel, A., Beyer, C., Kipp, M., et al. (2016) · Glia · doi:10.1002/glia.23058 · Cited by 95
Dimethyl fumarate does not mitigate cognitive decline and β-amyloidosis in female APPPS1 mice
Möhle, L., Brackhan, M., Bascuñana, P., & Pahnke, J. (2021) · Brain Research · doi:10.1016/j.brainres.2021.147579 · Cited by 21
Parodi, B., Sanna, A., Cedola, A., Uccelli, A., & Kerlero de Rosbo, N. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.655212 · Cited by 20
“Treatment with DMF ameliorates the clinical course of experimental autoimmune encephalomyelitis (EAE), the model for MS, in wild-type, but not HCAR2-deficient, mice by reducing the infiltration of neutrophils involved in disease progression (7).”
Background
Metadata
- Authors
- Chen, H., Assmann, J. C., Krenz, A., Rahman, M., Grimm, M., Karsten, C. M., Köhl, J., Offermanns, S., Wettschureck, N., & Schwaninger, M.
- Venue
- Journal of Clinical Investigation
- Published
- 2014-04-01
- Volume
- 124
- Issue
- 5
- Pages
- 2188-2192
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W1972403093
- Cited by
- 297
- References
- 25
- FWCI
- 20.72
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.